Portal de Periódicos da CAPES

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

2017; Taylor & Francis; Volume: 58; Issue: 12 Linguagem: Inglês

10.1080/10428194.2017.1323267

1042-8194

Juan Eduardo Megías‐Vericat, Pau Montesinos, Marí­a José Herrero, Federico Moscardó, Virginia Bosó, David Martínez‐Cuadrón, Luis Rojas, Rebeca Rodríguez‐Veiga, Blanca Boluda, Luis Sendra, José Cervera, José Luís Poveda, Miguel Á. Sanz, Salvador F. Aliño,

Hemoglobinopathies and Related Disorders

Cytarabine is considered the most effective chemotherapeutic option in acute myeloid leukemia (AML). The impact of 10 polymorphisms in cytarabine metabolic pathway genes were evaluated in 225 adult de novo AML patients. Variant alleles of DCK rs2306744 and CDA rs602950 showed higher complete remission (p = .024, p = .045), with lower survival rates for variant alleles of CDA rs2072671 (p = .015, p = .045, p = .032), rs3215400 (p = .033) and wild-type genotype of rs602950 (p = .039, .014). Induction death (p = .033) and lower survival rates (p = .021, p = .047) were correlated to RRM1 rs9937 variant allele. In addition, variant alleles of CDA rs532545 and rs602950 were related to skin toxicity (p = .031, p = .049) and mucositis to DCK rs2306744 minor allele (p = .046). Other toxicities associated to variant alleles were hepatotoxicity to NT5C2 rs11598702 (p = .032), lung toxicity (p = .031) and thrombocytopenia to DCK rs4694362 (p = .046). This study supports the interest of cytarabine pathway polymorphisms regarding efficacy and toxicity of AML therapy in a coherent integrated manner.